Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAWH Ascend Wellness	$0.81 +4.5%	$0.45	$0.26 ▼ $1.02	$165.60M	1.04	157,812 shs	680,619 shs
CRBP Corbus Pharmaceuticals	$10.01 -4.4%	$8.69	$4.64 ▼ $61.72	$123.35M	3.2	183,234 shs	46,415 shs
IGXT IntelGenx Technologies	$0.17	$0.17	$0.09 ▼ $0.22	$29.17M	2.47	N/A	N/A
ZNTL Zentalis Pharmaceuticals	$1.77 -3.0%	$1.43	$1.01 ▼ $5.44	$127.33M	1.71	1.22 million shs	389,731 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAWH Ascend Wellness	+6.16%	+37.17%	+84.09%	+131.34%	-15.76%
CRBP Corbus Pharmaceuticals	+4.39%	+13.56%	+9.18%	+37.40%	-81.71%
IGXT IntelGenx Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
ZNTL Zentalis Pharmaceuticals	-1.62%	+10.98%	+26.39%	+45.60%	-40.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAWH Ascend Wellness	1.8766 of 5 stars	0.0	5.0	0.0	0.0	3.3	1.7	0.6
CRBP Corbus Pharmaceuticals	4.4043 of 5 stars	3.6	3.0	0.0	4.7	3.6	2.5	0.0
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	1.8172 of 5 stars	3.3	2.0	0.0	0.0	2.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAWH Ascend Wellness	1.00	Sell	N/A	N/A
CRBP Corbus Pharmaceuticals	3.10	Buy	$49.00	389.76% Upside
IGXT IntelGenx Technologies	0.00	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	2.67	Moderate Buy	$8.20	364.59% Upside

Current Analyst Ratings Breakdown

Latest IGXT, AAWH, ZNTL, and CRBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	AAWH Ascend Wellness	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/7/2025	ZNTL Zentalis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2025	ZNTL Zentalis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $5.00
8/6/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $53.00
7/30/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$28.00
7/12/2025	CRBP Corbus Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAWH Ascend Wellness	$518.59M	0.32	$0.12 per share	6.64	$0.69 per share	1.17
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$9.06 per share	N/A
IGXT IntelGenx Technologies	$1.04M	28.05	N/A	N/A	($0.07) per share	-2.39
ZNTL Zentalis Pharmaceuticals	$67.43M	1.89	N/A	N/A	$3.81 per share	0.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAWH Ascend Wellness	-$48.21M	-$0.42	N/A	N/A	N/A	-15.47%	-72.18%	-9.55%	N/A
CRBP Corbus Pharmaceuticals	-$40.21M	-$4.76	N/A	N/A	N/A	N/A	-43.65%	-39.62%	11/6/2025 (Estimated)
IGXT IntelGenx Technologies	-$9.93M	-$0.06	N/A	∞	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	-$165.84M	-$2.26	N/A	N/A	N/A	N/A	-51.62%	-40.28%	11/11/2025 (Estimated)

Latest IGXT, AAWH, ZNTL, and CRBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	ZNTL Zentalis Pharmaceuticals	-$0.56	-$0.37	+$0.19	-$0.37	N/A	N/A
8/5/2025	Q2 2025	CRBP Corbus Pharmaceuticals	-$1.55	-$1.44	+$0.11	-$1.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAWH Ascend Wellness	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAWH Ascend Wellness	2.61	1.47	0.80
CRBP Corbus Pharmaceuticals	N/A	9.21	9.21
IGXT IntelGenx Technologies	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	7.99	7.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAWH Ascend Wellness	17.31%
CRBP Corbus Pharmaceuticals	64.64%
IGXT IntelGenx Technologies	N/A
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AAWH Ascend Wellness	22.08%
CRBP Corbus Pharmaceuticals	3.60%
IGXT IntelGenx Technologies	42.05%
ZNTL Zentalis Pharmaceuticals	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAWH Ascend Wellness	2,300	204.44 million	166.44 million	Not Optionable
CRBP Corbus Pharmaceuticals	40	12.26 million	11.81 million	Optionable
IGXT IntelGenx Technologies	38	174.66 million	101.21 million	Not Optionable
ZNTL Zentalis Pharmaceuticals	160	72.14 million	70.76 million	Optionable

IGXT, AAWH, ZNTL, and CRBP Headlines

Recent News About These Companies

Zentalis Pharmaceuticals Announces New Chief Legal Officer

August 26 at 9:45 PM | msn.com

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

August 26 at 4:05 PM | globenewswire.com

Guggenheim Remains a Buy on Zentalis Pharmaceuticals (ZNTL)

August 19, 2025 | theglobeandmail.com

Zentalis Pharmaceuticals (ZNTL) Gets a Buy from TD Cowen

August 18, 2025 | theglobeandmail.com

Zentalis (ZNTL) Q2 Loss Narrows 70%

August 18, 2025 | theglobeandmail.com

Leerink Partnrs Has Pessimistic View of ZNTL Q3 Earnings

August 11, 2025 | marketbeat.com

Equities Analysts Offer Predictions for ZNTL Q3 Earnings

August 11, 2025 | marketbeat.com

HC Wainwright Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to "Strong-Buy"

August 10, 2025 | marketbeat.com

Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold

August 10, 2025 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

August 9, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Primecap Management Co. CA

August 9, 2025 | marketbeat.com

Zentalis price target lowered to $5 from $6 at Wells Fargo

August 8, 2025 | msn.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $5.00 by Analysts at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.

August 7, 2025 | marketbeat.com

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

August 6, 2025 | globenewswire.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by Brokerages

August 6, 2025 | marketbeat.com

GSA Capital Partners LLP Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

August 3, 2025 | marketbeat.com

Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Friday

August 1, 2025 | marketbeat.com

Decheng Capital LLC Lowers Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

July 30, 2025 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company

July 24, 2025 | finance.yahoo.com

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGXT, AAWH, ZNTL, and CRBP Company Descriptions

Ascend Wellness OTC:AAWH

$0.81 +0.04 (+4.52%)

As of 03:23 PM Eastern

Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.

Corbus Pharmaceuticals NASDAQ:CRBP

$10.01 -0.47 (-4.44%)

As of 03:41 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

IntelGenx Technologies OTCMKTS:IGXT

$0.17 0.00 (0.00%)

As of 05/27/2025

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.76 -0.06 (-3.02%)

As of 03:41 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time